Update shared on10 Aug 2025
Fair value Decreased 5.71%Despite an upward revision in revenue growth forecasts and a lower future P/E, the analyst consensus price target for Inogen has decreased from $11.67 to $11.00, indicating increased caution around the company’s fair value.
What's in the News
- Inogen expects third quarter 2025 revenue of $91–93 million (~4% YoY growth) and full-year 2025 revenue of $354–357 million (~6% YoY growth).
- Launched VoxiTM 5, a new stationary oxygen concentrator for the US long-term care market, expanding product portfolio and market potential; features include quiet operation, compact design with casters, 3-year warranty, and advanced filtration.
Valuation Changes
Summary of Valuation Changes for Inogen
- The Consensus Analyst Price Target has fallen from $11.67 to $11.00.
- The Consensus Revenue Growth forecasts for Inogen has significantly risen from 5.7% per annum to 6.5% per annum.
- The Future P/E for Inogen has fallen from 9.40x to 8.84x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.